Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts

Nivolumab, anti-PD1 mAb, is approved for 2nd line R-M HNC, but only 15–20% of patients will benefit [3]. [...]there is an unmet need for robust predictive markers for patient selection. TNF-α and IFN-γ increased at TPD. [...]combination of IL-5, IL-6, CD3+CD8+LAG3+, CD3+CD8+PD1+LAG3+ and CD8+TEMRA basal levels might predict which patients could benefit from the treatment. In mismatch repair deficient (dMMR) colon cancer patients programmed death 1 (PD-1) blockade is highly effective in metastatic setting and plus cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade induced high pathological response rate in early stages. At surgery tumors from NICOLE cohort showed significantly higher level of CD8 T-cells infiltration (p =